Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT

RCT (n=463) found aflibercept was non-inferior to ranibizumab for best corrected visual acuity (VA) change, but not superior. It could not be ruled out that bevacizumab is worse than these two agents by 5 VA letters, though on economic analysis, it was the most cost-effective.

Source:

National Institute for Health Research